Adverse Event Reporting & SAE Management

Future Trends: AI, Automation and Real-World Data in Communication with IRB/Regulators

Posted on By digi

Future Trends: AI, Automation and Real-World Data in Communication with IRB/Regulators In today’s complex clinical trial landscape, effective communication with Institutional Review Boards (IRBs) and regulators is paramount. As the industry evolves, trends such as artificial intelligence (AI), automation, and the incorporation of real-world data are transforming how clinical research professionals engage with these stakeholders….

Read More “Future Trends: AI, Automation and Real-World Data in Communication with IRB/Regulators” »

Communication with IRB/Regulators

Global Considerations for Communication with IRB/Regulators Across US, EU and UK Programs

Posted on By digi

Global Considerations for Communication with IRB/Regulators Across US, EU and UK Programs Effective communication with Institutional Review Boards (IRBs) and regulatory agencies is critical to ensuring the integrity and compliance of clinical trials conducted across the US, UK, and EU. Given the complexities of regulatory environments, clinical operations, regulatory affairs, and medical affairs professionals must…

Read More “Global Considerations for Communication with IRB/Regulators Across US, EU and UK Programs” »

Communication with IRB/Regulators

Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators

Posted on By digi

Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators Effective communication between clinical trial sponsors, investigators, and Institutional Review Boards (IRBs) or regulators is crucial for the success of any clinical trial. This comprehensive guide, aimed at clinical operations, regulatory affairs, and medical affairs…

Read More “Data Quality and Reconciliation Controls for Robust Communication with IRB/Regulators” »

Communication with IRB/Regulators

Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs

Posted on By digi

Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs Clinical trials are essential for the development of new therapeutics. Within these studies, safety is paramount. Unblinding procedures, particularly for safety reasons, play a crucial role in protecting subjects while ensuring…

Read More “Unblinding for Safety Reasons in Practice: Step-by-Step Guide for Sponsors and CROs” »

Unblinding for Safety Reasons

How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations

Posted on By digi

How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations Introduction to Unblinding in Clinical Trials Unblinding in clinical trials is a critical process that allows researchers and clinicians to access necessary data regarding the safety and…

Read More “How to Design Unblinding for Safety Reasons That Meets FDA, EMA and MHRA Expectations” »

Unblinding for Safety Reasons

Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials

Posted on By digi

Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials Introduction to Unblinding in Clinical Trials In the context of good lab clinical trials, unblinding refers to the process of revealing the treatment allocation to clinical trial participants, particularly when safety concerns arise….

Read More “Unblinding for Safety Reasons: End-to-End Compliance Framework for Global Clinical Trials” »

Unblinding for Safety Reasons

Digital Tools and Automation to Streamline Unblinding for Safety Reasons

Posted on By digi

Digital Tools and Automation to Streamline Unblinding for Safety Reasons Digital Tools and Automation to Streamline Unblinding for Safety Reasons 1. Introduction to Unblinding in Clinical Trials The process of unblinding in clinical trials is a critical aspect, particularly when unanticipated adverse events (AEs) occur that necessitate immediate access to treatment assignments. unblinding plays a…

Read More “Digital Tools and Automation to Streamline Unblinding for Safety Reasons” »

Unblinding for Safety Reasons

Aligning Unblinding for Safety Reasons With GCP, ICH E2A–E2F and Local Regulations

Posted on By digi

Aligning Unblinding for Safety Reasons With GCP, ICH E2A–E2F and Local Regulations In the context of clinical research, unblinding refers to the process of revealing the treatment assignment for a clinical trial participant. While blinding is essential to ensure the integrity of clinical trial data, unblinding for safety reasons necessitates careful consideration and adherence to…

Read More “Aligning Unblinding for Safety Reasons With GCP, ICH E2A–E2F and Local Regulations” »

Unblinding for Safety Reasons

Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings

Posted on By digi

Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings In the realm of clinical research, the integrity of trial results is paramount. Unblinding, which is the process of revealing the treatment assignments of participants, is sometimes necessary for safety reasons. However, incorrect handling of unblinding can lead to erroneous data, compromised study…

Read More “Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings” »

Unblinding for Safety Reasons

Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings

Posted on By digi

Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings In the realm of clinical research, unblinding for safety reasons is an essential process that requires precise adherence to regulatory guidelines. The duty to maintain patient safety while simultaneously upholding the integrity of clinical trial data often presents operational challenges. This article will…

Read More “Common Pitfalls in Unblinding for Safety Reasons—and How to Avoid Regulatory Findings” »

Unblinding for Safety Reasons